Decreased circulating levels of tumor necrosis factor-α in postmenopausal women during consumption of soy-containing isoflavones

Journal of Clinical Endocrinology and Metabolism

Volumn 90, Issue 7, 2005, Pages 3956-3962

  Huang, Yafei ^a   Cao, Shimin ^a   Nagamani, Manubai ^a   Anderson, Karl E ^a   Grady, James J ^a   Lu, Lee Jane W ^a  

^a University of Texas Medical Branch School of Medicine   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOKINE; DAIDZEIN; ESTRADIOL; GENISTEIN; INTERLEUKIN 1ALPHA; INTERLEUKIN 6; ISOFLAVONE; LIPOPOLYSACCHARIDE; TAMOXIFEN; TUMOR NECROSIS FACTOR ALPHA;

ADULT; ANTIINFLAMMATORY ACTIVITY; ARTICLE; BLOOD SAMPLING; CANCER; CONTROLLED STUDY; DIET SUPPLEMENTATION; FEMALE; FOOD INTAKE; HUMAN; HUMAN EXPERIMENT; IMMUNOMODULATION; LEUKOCYTE COUNT; MONOCYTE; NORMAL HUMAN; OSTEOLYSIS; POSTMENOPAUSE; PRIORITY JOURNAL; PROPHYLAXIS; SOYBEAN MILK;

AGED; CELLS, CULTURED; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; GENISTEIN; HUMANS; INTERLEUKIN-1; INTERLEUKIN-6; ISOFLAVONES; LONGITUDINAL STUDIES; MIDDLE AGED; MONOCYTES; POSTMENOPAUSE; SOYBEANS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 23044500682     PISSN: 0021972X     EISSN: None     Source Type: Journal    
DOI: 10.1210/jc.2005-0161     Document Type: Article

References (60)

1. Rosenblum MG, Donato NJ 1989 Tumor necrosis factor α: a multifaceted peptide hormone. Crit Rev Immunol 9:21-44
2. Nanes MS 2003 Tumor necrosis factor-α: molecular and cellular mechanisms in skeletal pathology. Gene 321:1-15
3. Tracey KJ, Cerami A 1994 Tumor necrosis factor: a pleiotropic cytokine and therapeutic target. Annu Rev Med 45:491-503
4. Normark S, Nilsson C, Normark BH, Hornef MW 2004 Persistent infection with Helicobacter pylori and the development of gastric cancer. Adv Cancer Res 90:63-89
5. Lin EY, Pollard JW 2004 Macrophages: modulators of breast cancer progression. Novartis Found Symp 256:158-168
6. Lucia MS, Torkko KC 2004 Inflammation as a target for prostate cancer chemoprevention: pathological and laboratory rationale. J Urol 171:S30-S34
7. Fujiki H, Suganuma M, Okabe S, Kurusu M, Imai K, Nakachi K 2002 Involvement of TNF-α changes in human cancer development, prevention and palliative care. Mech Ageing Dev 123:1655-1663
8. Suganuma M, Okabe S, Marino MW, Sakai A, Sueoka E, Fujiki H 1999 Essential role of tumor necrosis factor α (TNF-α) in tumor promotion as revealed by TNF-α-deficient mice. Cancer Res 59:4516-4518
9. Pikarsky E, Porat RM, Stein I, Abramovitch R, Amit S, Kasem S, Gutkovich-Pyest E, Urieli-Shoval S, Galun E, Ben-Neriah Y 2004 NF-κB functions as a tumour promoter in inflammation-associated cancer. Nature 431:461-466
10. Spriggs DR, Imamura K, Rodriguez C, Sariban E, Kufe DW 1988 Tumor necrosis factor expression in human epithelial tumor cell lines. J Clin Invest 81:455-460
11. Wu S, Boyer CM, Whitaker RS, Berchuck A, Wiener JR, Weinberg JB, Bast RCJ 1993 Tumor necrosis factor α as an autocrine and paracrine growth factor for ovarian cancer: monokine induction of tumor cell proliferation and tumor necrosis factor α expression. Cancer Res 53:1939-1944
12. Miles DW, Happerfield LC, Naylor MS, Bobrow LG, Rubens RD, Balkwill FR 1994 Expression of tumour necrosis factor (TNF α) and its receptors in benign and malignant breast tissue. Int J Cancer 56:777-782
13. Leek RD, Landers R, Fox SB, Ng F, Harris AL, Lewis CE 1998 Association of tumour necrosis factor α and its receptors with thymidine phosphorylase expression in invasive breast carcinoma. Br J Cancer 77:2246-2251
14. Dayer JM, Beutler B, Cerami A 1985 Cachectin/tumor necrosis factor stimulates collagenase and prostaglandin E2 production by human synovial cells and dermal fibroblasts. J Exp Med 162:2163-2168
15. Frater-Schroder M, Risau W, Hallmann R, Gautschi P, Bohlen P 1987 Tumor necrosis factor type α, a potent inhibitor of endothelial cell growth in vitro, is angiogenic in vivo. Proc Natl Acad Sci USA 84:5277-5281
16. Orosz P, Echtenacher B, Falk W, Ruschoff J, Weber D, Mannel DN 1993 Enhancement of experimental metastasis by tumor necrosis factor. J Exp Med 177:1391-1398
17. Pfeilschifter J, Koditz R, Pfohl M, Schatz H 2002 Changes in proinflammatory cytokine activity after menopause. Endocr Rev 23:90-119
18. Rickard D, Russell G, Gowen M 1992 Oestradiol inhibits the release of tumour necrosis factor but not interleukin 6 from adult human osteoblasts in vitro. Osteoporos Int 2:94-102
19. Wang X, Schwartz Z, Yaffe P, Ornoy A 1999 The expression of transforming growth factor-β and interleukin-1β mRNA and the response to 1,25(OH)2D3′ 17β-estradiol, and testosterone is age dependent in primary cultures of mouse-derived osteoblasts in vitro. Endocrine 11:13-22
20. Ralston SH, Russell RG, Gowen M 1990 Estrogen inhibits release of tumor necrosis factor from peripheral blood mononuclear cells in postmenopausal women. J Bone Miner Res 5:983-988
21. Pacifici R, Brown C, Puscheck E, Friedrich E, Slatopolsky E, Maggio D, McCracken R, Avioli LV 1991 Effect of surgical menopause and estrogen replacement on cytokine release from human blood mononuclear cells. Proc Natl Acad Sci USA 88:5134-5138
22. Shanker G, Sorci-Thomas M, Adams MR 1994 Estrogen modulates the expression of tumor necrosis factor α mRNA in phorbol ester-stimulated human monocytic THP-1 cells. Lymphokine Cytokine Res 13:377-382
23. Kimble RB, Srivastava S, Ross FP, Matayoshi A, Pacifici R 1996 Estrogen deficiency increases the ability of stromal cells to support murine osteoclastogenesis via an interleukin-1 and tumor necrosis factor-mediated stimulation of macrophage colony-stimulating factor production. J Biol Chem 271:28890-28897
24. Bernard-Poenaru O, Roux C, Blanque R, Gardner C, de Vemejoul MC, Cohen-Solal ME 2001 Bone-resorbing cytokines from peripheral blood mononuclear cells after hormone replacement therapy: a longitudinal study. Osteoporos Int 12:769-776
25. Rogers A, Eastell R 2001 The effect of 17β-estradiol on production of cytokines in cultures of peripheral blood. Bone 29:30-34
26. Ito A, Bebo BFJ, Matejuk A, Zamora A, Silverman M, Fyfe-Johnson A, Offner H 2001 Estrogen treatment down-regulates TNF-α production and reduces the severity of experimental autoimmune encephalomyelitis in cytokine knockout mice. J Immunol 167:542-552
27. Cantatore FP, Loverro G, Ingrosso AM, Lacanna R, Sassanelli E, Selvaggi L, Carrozzo M 1995 Effect of oestrogen replacement on bone metabolism and cytokines in surgical menopause. Clin Rheumatol 14:157-160
28. Kamada M, Irahara M, Maegawa M, Ohmoto Y, Takeji T, Yasui T, Aono T 2001 Postmenopausal changes in serum cytokine levels and hormone replacement therapy. Am J Obstet Gynecol 184:309-314
29. Puder JJ, Freda PU, Goland RS, Wardlaw SL 2001 Estrogen modulates the hypothalamic-pituitary-adrenal and inflammatory cytokine responses to endotoxin in women. J Clin Endocrinol Metab 86:2403-2408
30. Gianni W, Raloxifene modulate IL-6 and TNF-α synthesis in vitro: results from a clinical pilot study. Program of the 86th Annual Meeting of The Endocrine Society, New Orleans, LA, 2004 (Abstract P2-517)
31. An J, Ribeiro RC, Webb P, Gustafsson JA, Kushner PJ, Baxter JD, Leitman DC 1999 Estradiol repression of tumor necrosis factor-α transcription requires estrogen receptor activation function-2 and is enhanced by coactivators. Proc Natl Acad Sci USA 96:15161-15166
32. Cuzzocrea S, Santagati S, Sautebin L, Mazzon E, Calabro G, Serraino I, Caputi AP, Maggi A 2000 17β-estradiol antiinflammatory activity in carrageenan-induced pleurisy. Endocrinology 141:1455-1463
33. Miksicek RJ 1995 Estrogenic flavonoids: structural requirements for biological activity. Proc Soc Exp Biol Med 208:44-50
34. Hargreaves DF, Potten CS, Harding C, Shaw LE, Morton MS, Roberts SA Howell A, Bundred NJ 1999 Two-week dietary soy supplementation has an estrogenic effect on normal premenopausal breast. J Clin Endocrinol Metab 84:4017-4024
35. Miyazaki K 2004 Novel approach for evaluation of estrogenic and anti-estrogenic activities of genistein and daidzein using B16 melanoma cells and dendricity assay. Pigment Cell Res 17:407-412
36. Lu LJ, Anderson KE, Grady JJ, Kohen F, Nagamani M 2000 Decreased ovarian hormones during a soya diet: implications for breast cancer prevention. Cancer Res 60:4112-4121
37. Kohen F, Gayer B, Amir-Zaltsman Y, Ben-Hur H, Thomas E, Lu LJ 1999 A nonisotopic enzyme-based immunoassay for assessing human exposure to genistein. Nutr Cancer 35:96-103
38. Setchell KD, Brown NM, Desai P, Zimmer-Nechemias P, Wolfe BE, Brashear WT, Kirschner AS, Cassidy A, Heubi JE 2001 Bioavailability of pure isoflavones in healthy humans and analysis of commercial soy isoflavone supplements. J Nutr 131:1362S-1375S
39. Xaus J, Comalada M, Valledor AF, Lloberas J, Lopez-Soriano F, Argiles JM, Bogdan C, Celada A 2000 LPS induces apoptosis in macrophages mostly through the autocrine production of TNF-α. Blood 95:3823-3831
40. DeForge LE, Remick DG 1991 Kinetics of TNF, IL-6, and IL-8 gene expression in LPS-stimulated human whole blood. Biochem Biophys Res Commun 174:18-24
41. Persky V, Van Horn L 1995 Epidemiology of soy and cancer: perspectives and directions. J Nutr 125:709S-712S
42. Fujiki H, Suganuma M, Okabe S, Sueoka E, Suga K, Imai K, Nakachi K 2000 A new concept of tumor promotion by tumor necrosis factor-α, and cancer preventive agents (-)-epigallocatechin gallate and green tea - a review. Cancer Detect Prev 24:91-99
43. Sporn MB, Roberts AB 1992 Transforming growth factor-β: recent progress and new challenges. J Cell Biol 119:1017-1021
44. Starkie RL, Rolland J, Angus DJ, Anderson MJ, Febbraio MA 2001 Circulating monocytes are not the source of elevations in plasma IL-6 and TNF-α levels after prolonged running. Am J Physiol Cell Physiol 280:C769-C774
45. Rassi CM, Lieberherr M, Chaumaz G, Pointillart A, Cournot G 2002 Down-regulation of osteoclast differentiation by daidzein via caspase 3. J Bone Miner Res 17:630-638
46. Ben-Hur H, Mor G, Insler V, Blickstein I, Amir-Zaltsman Y, Sharp A, Globerson A, Kohen F 1995 Menopause is associated with a significant increase in blood monocyte number and a relative decrease in the expression of estrogen receptors in human peripheral monocytes. Am J Reprod Immunol 34:363-369
47. Suh KS, Koh G, Park CJ, Woo JT, Kim SW, Kim JW, Park IK, Kim YS 2003 Soybean isoflavones inhibit tumor necrosis factor-α-induced apoptosis and the production of interleukin-6 and prostaglandin E2 in osteoblastic cells. Phytochemistry 63:209-215
48. Joo SS, Kang HC, Lee MW, Choi YW, Lee DI 2003 Inhibition of IL-1β and IL-6 in osteoblast-like cell by isoflavones extracted from Sophorae fructus. Arch Pharm Res 26:1029-1035
49. Chen X, Garner SC, Quarles LD, Anderson JJ 2003 Effects of genistein on expression of bone markers during MC3T3-E1 osteoblastic cell differentiation. J Nutr Biochem 14:342-349
50. Rickard DJ, Monroe DG, Ruesink TJ, Khosla S, Riggs BL, Spelsberg TC 2003 Phytoestrogen genistein acts as an estrogen agonist on human osteoblastic cells through estrogen receptors α and β. J Cell Biochem 89:633-664
51. Bouchardy C, Verkooijen HM, Fioretta G, Sappino AP, Vlastos G 2002 Increased risk of malignant müllerian tumor of the uterus among women with breast cancer treated by tamoxifen. J Clin Oncol 20:4403
52. Yoneda K, Tanji Y, Ikeda N, Miyoshi Y, Taguchi T, Tamaki Y, Noguchi S 2002 Influence of adjuvant tamoxifen treatment on bone mineral density and bone turnover markers in postmenopausal breast cancer patients in Japan. Cancer Lett 186:223-230
53. Williams JP, McKenna MA, Thames AM, McDonald JM 2000 Tamoxifen inhibits phorbol ester stimulated osteoclastic bone resorption: an effect mediated by calmodulin. Biochem Cell Biol 78:715-723
54. Mitchell JH, Gardner PT, McPhail DB, Morrice PC, Collins AR, Duthie GG 1998 Antioxidant efficacy of phytoestrogens in chemical and biological model systems. Arch Biochem Biophys 360:142-148
55. Lamartiniere CA, Murrill WB, Manzolillo PA, Zhang JX, Barnes S, Zhang X, Wei H, Brown NM 1998 Genistein alters the ontogeny of mammary gland development and protects against chemically-induced mammary cancer in rats. Proc Soc Exp Biol Med 217:358-364
56. Zhou JR, Mukherjee P, Gugger ET, Tanaka T, Blackburn GL, Clinton SX 1998 Inhibition of murine bladder tumorigenesis by soy isoflavones via alterations in the cell cycle, apoptosis, and angiogenesis. Cancer Res 58:5231-5238
57. Akiyama T, Ishida J, Nakagawa S, Ogawara H, Watanabe S, Itoh N, Shibuya, Fukami Y 1987 Genistein, a specific inhibitor of tyrosine-specific protein kinases. J Biol Chem 262:5592-5595
58. Markovits J, Linassier C, Fosse P, Couprie J, Pierre J, Jacquemin-Sablon A, Saucier JM, Le Pecq JB, Larsen AK 1989 Inhibitory effects of the tyrosine kinase inhibitor genistein on mammalian DNA topoisomerase II. Cancer Res 49:5111-5117
59. Wang W, Higuchi CM, Zhang R 1997 Individual and combinatory effects of soy isoflavones on the in vitro potentiation of lymphocyte activation. Nutr Cancer 29:29-34
60. Walsh BW, Cox DA, Sashegyi A, Dean RA, Tracy RP, Anderson PW 2001 Role of tumor necrosis factor-α and interleukin-6 in the effects of hormone replacement therapy and raloxifene on C-reactive protein in postmenopausal women. Am J Cardiol 88:825-882